One of the major advances in Alzheimer’s disease over the past two decades has been the development and validation of biomarkers.1 What impact will biomarker testing have on the early detection of Alzheimer’s disease? What will it mean for patients?
Biomarkers have the potential to push the limits of early detection into uncharted territory. On this MindChangers podcast episode, Prof Chris Rowe and Dr Qiao-Xin Li discuss how PET imaging and CSF biomarker testing are about to change the diagnosis of Alzheimer’s disease.
Innovative new technologies have the potential to make biomarker testing for Alzheimer’s disease quicker, easier and less invasive for patients. A/Prof Peter van Wijngaarden and Prof Ashley Bush discuss what is on the horizon in this episode of the MindChangers podcast.
References: 1. Khoury R, Ghossoub, E. Neuropsychiatry. 2019;1(100005):1–6. 2. Jack CR Jr et al. Alzheimers Dement. 2018;14(4):535–62. 3. Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging. 1998;19(2):109–16.